Business UpdateJul 10, 2026, 07:25 PM
Alamar Biosciences NULISA Platform Featured at AAIC with 140+ Presentations
AI Summary
Alamar Biosciences announced its NULISA platform will be prominently featured at the Alzheimer's Association International Conference (AAIC) in London, with over 140 posters and presentations. This significant increase in data presentation, more than four times the previous AAIC, highlights the widespread adoption of NULISA and ARGO HT technologies in Alzheimer's research. The company will also host a workshop to present new data on eMTBR-Tau and BD-pTau217, two highly specific Alzheimer's blood indicators, demonstrating the platform's potential for earlier detection and more precise disease staging.
Key Highlights
- Alamar Biosciences' NULISA platform featured in over 140 presentations at AAIC.
- This represents more than four times the presentations from the previous AAIC.
- Company to host a workshop on multiplex protein profiling for Alzheimer's insights.
- New data on eMTBR-Tau and BD-pTau217 to be presented at the workshop.
- These are two highly specific Alzheimer's blood indicators measured on NULISA.
- Combined measurement of BD-pTau217 and eMTBR-Tau enhances diagnostic ability.
- NULISA platform measures over 220 disease-related proteins in a single assay.
Price Impact
More from ALMR